SARS-CoV-2 nucleocapsid induces hyperinflammation and vascular leakage through the Toll-like receptor signaling axis in macrophages

Read full text
Authors: Zhenlan Yao, Pablo A. Alvarez, Carolina A. Chavez, Yennifer Delgado, Prashant Kaushal, David Austin, David Austin, Qian Li, Yanying Yu, Anne Zaiss, Vaithilingaraja Arumugaswami, Qiang Ding
+6 more Jeffrey J. Hsu, Robert D. Damoiseaux, Hector C. Aguilar, Mehdi Bouhaddou, Alexander Hoffmann, Melody M. H. Li
Cited by: 1
References: 65

Abstract

A substantial proportion of hospitalized COVID-19 patients require ICU admission, often associated with an imbalance between antiviral responses and inflammatory signaling leading to uncontrolled cytokine secretion. The SARS-CoV-2 nucleocapsid (N) protein is a known immune antagonist, but its role in macrophage-driven cytokine storms is unclear. We demonstrate that N functions in a stimulus-specific manner, specifically amplifying extracellular and dampening intracellular RNA sensing. Moreover, we show that this is a conserved feature of pathogenic betacoronaviruses through distinct mechanisms. Our interaction networks with SARS-CoV-2 variant N proteins suggest that the Delta variant N drives inflammation through interactions with several proteins, most notably, cGAS. Profiling of secreted cytokines revealed that N disrupts the secretome in a variant-specific manner. Most notably, we found that supernatants from the Delta variant N-expressing macrophages dramatically disrupt heart endothelial barriers, implicating N in COVID-19-associated cardiac complications. Our findings highlight N-mediated immune imbalance as a driver of severe COVID-19 and identify N as a promising therapeutic target to mitigate hyperinflammation.

Fields of Study & Subjects

COVID-19 Clinical Research Studies SARS-CoV-2 and COVID-19 Research Inflammasome and immune disorders

Publication details

Journal / source
Science Advances
Publisher
American Association for the Advancement of Science (AAAS)
Volume
12
Issue
32
Pages
eaea2780–eaea2780
Publication date
5 August 2026
Language
EN